Tuesday , November 21 2017
Home / Therapies / Sulfonylurea (page 4)

Sulfonylurea

FDA Approves Xigduo XR, a New Dapagliflozin-Metformin Combination

The once-daily oral tablet is the first in the U.S. to combine the SGLT-2 inhibitor dapagliflozin with the biguanide extended-release (XR) metformin hydrochloride.. The US Food and Drug Administration (FDA) has approved a once-daily combination of dapagliflozin and metformin hydrochloride extended-release (Xigduo XR, AstraZeneca) for the treatment of adults with …

Read More »

DPP-4 Inhibitors in Combination with Insulin Therapy for Type 2 Diabetes Patients

The addition of a DPP-4 inhibitor decreased HbA1C while not requiring an increase in insulin, and subjects remained weight neutral without experiencing an increase in hypoglycemic events… Currently approved dipeptidyl peptidase-4 (DPP-4) inhibitors include alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin. DPP-4 inhibitors work by enhancing glucose dependent insulin secretion and …

Read More »

Metformin Is Best Initial Oral Drug for Lowering Glucose Levels in Diabetes Patients

Metformin, sulfonylureas, thiazolidinedione, and DPP-4 inhibitors were compared to evaluate the effects on the time to subsequent treatment… There are many classes of oral drugs used for diabetes therapy, but there is a lack of evidence as to which drug is best for use as initial therapy. Most patients diagnosed …

Read More »

GLP-1 Receptor Agonist a Treatment Option in Type 2 Patients with Renal Insufficiency

Phase 3 trial demonstrates the safety and efficacy of albiglutide in type 2 diabetes patients with renal impairment…. Renal impairment is a common comorbid condition in type 2 diabetes patients with reported incidence rates as high as 35%. Those with renal insufficiency often find their diabetes treatment options limited. Possible …

Read More »